New Trends Approved in Management of Dyslipidaemia

Abdulaziz Aboshahba
{"title":"New Trends Approved in Management of Dyslipidaemia","authors":"Abdulaziz Aboshahba","doi":"10.19080/jocct.2019.14.555894","DOIUrl":null,"url":null,"abstract":"Hypercholesterolemia increases the risk of atherosclerotic cardiovascular disease and is incompletely reversed by statin therapy alone in many patients. Familial hypercholesterolemia (FH) is a common genetic cause of premature cardiovascular disease (CVD). So, most of efforts and directions focused on new therapies as PCSK9 gene was identified in the past decade as a potential therapeutic target for the management of patients with hypercholesterolemia which monoclonal antibodies, Lomitapide, Mipomersen and other therapies hoping to reduce risk of hypercholesterolemia. The novel therapies are aiming for better lipid-lowering effects, fewer side effects and improved clinical outcomes.","PeriodicalId":73635,"journal":{"name":"Journal of cardiology & cardiovascular therapy","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of cardiology & cardiovascular therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.19080/jocct.2019.14.555894","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Hypercholesterolemia increases the risk of atherosclerotic cardiovascular disease and is incompletely reversed by statin therapy alone in many patients. Familial hypercholesterolemia (FH) is a common genetic cause of premature cardiovascular disease (CVD). So, most of efforts and directions focused on new therapies as PCSK9 gene was identified in the past decade as a potential therapeutic target for the management of patients with hypercholesterolemia which monoclonal antibodies, Lomitapide, Mipomersen and other therapies hoping to reduce risk of hypercholesterolemia. The novel therapies are aiming for better lipid-lowering effects, fewer side effects and improved clinical outcomes.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
血脂异常治疗的新趋势
高胆固醇血症会增加动脉粥样硬化性心血管疾病的风险,在许多患者中,他汀类药物单独治疗无法完全逆转。家族性高胆固醇血症(FH)是早发性心血管疾病(CVD)的常见遗传原因。因此,大多数的努力和方向都集中在新疗法上,因为PCSK9基因在过去十年中被确定为治疗高胆固醇血症患者的潜在治疗靶点,单克隆抗体、洛米他、米波默森和其他疗法都希望降低高胆固醇血症的风险。这些新疗法旨在获得更好的降脂效果、更少的副作用和改善临床效果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Role of Cardiovascular Magnetic Resonance Imaging in Early Detection of Myocarditis in Patients Recovered from COVID-19 Ldl-c Levels In Secondary Prevention: The Lower The Better and The Sooner The Better Mechanical Pulmonary Valve Thrombosis: Recurrence and Response to Thrombolytic Therapy Ocular Ischemic Syndrome as a Clue for Carotid Artery Stenosis The results of Percutaneous Transcatheter Pulmonary valvuloplasty in Adult Patients
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1